Transdermal patch containing vauqueline and preparation method and application thereof

Abstract

The invention discloses transdermal patch containing vauqueline and a preparation method and an application thereof. The transdermal patch consists of a back sheet, a protective layer and a medicine-containing matrix layer, wherein the medicine-containing matrix layer consists of vauqueline, hydrophilie matrix and penetrating agent, wherein the penetrating agent is selected from one or more of azone, oleic acid, propanediol and menthol. The vauqueline patch has scientific and reasonable proportion. Particularly the hydrophilie matrix is adopted, so the loaded dosage can be increased, and the vauqueline is effectively promoted to be released through the adhesive layer so as to improve the bioavailability. Moreover, the vauqueline patch is proved in the Pharmacodynamics experiment that stable blood medicine concentration can be maintained after the percutaneous absorption of the vauqueline patch, good pain-killing and anti-inflammatory effect can be played when the toxicity thereof is prevented, the preparation process has strong maneuverability, and the industrialized production can be realized.

Description

Technical field: The invention relates to a patch, in particular to a strychnine-containing transdermal patch with anti-inflammatory and analgesic effects and a preparation method thereof. Background technique Strychnosnux vomica L., also known as Panax vomica, was first recorded in "Compendium of Materia Medica Volume Eighteen". The Liver and Spleen meridians have the effects of dredging collaterals, relieving pain, dispelling stagnation and reducing swelling, but their severe toxicity severely limits the clinical application of this medicinal material. Modern studies have shown that strychnine accounts for 15% to 30% of the total alkaloids in Strychnium, and is the most active alkaloid in Strychnium. Compared with strychnine, another main alkaloid in Strychnine, strychnine is less toxic but has strong analgesic and anti-inflammatory activities. The toxic dose of strychnine is 71 times that of oral administration and 45 times that of injection. Studies have proved that s...

AI Technical Summary

Problems solved by technology

The Chinese patent with the publication number CN1698612A discloses a "nano strychnine liposome transdermal spray preparation and its preparation method and application", which mainly uses liposome as a carrier to significantly improve the analgesic efficacy and reduce toxicity , but the disadvantage of this patented preparation is that it is administered by spray, and the absorption time of strychnine is relatively short. In order to maintain the drug effect, it must be continuously sprayed on the affected area for 30 minutes in clinical application, which is very inconvenient to use

Images